Intravenous Immunoglobulin Nonresponsive Symptomatic Myocarditis during the Acute Stage of Incomplete Kawasaki Disease

Youngsoo Sohn; Yeo Hyang Kim

doi:10.14776/piv.2015.22.3.206

Journal List > Pediatr Infect Vaccine > v.22(3) > 1095993

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Sohn and Kim: Intravenous Immunoglobulin Nonresponsive Symptomatic Myocarditis during the Acute Stage of Incomplete Kawasaki Disease

Case Report

Pediatr Infect Vaccine 2015;22(3):206-208.

Published online: 21 January 2015

DOI: https://doi.org/10.14776/piv.2015.22.3.206

Intravenous Immunoglobulin Nonresponsive Symptomatic Myocarditis during the Acute Stage of Incomplete Kawasaki Disease

Youngsoo Sohn, Yeo Hyang Kim

Department of Pediatrics, Kyungpook National University School of Medicine, Daegu, Korea

Correspondence: Yeo Hyang Kim Department of Pediatrics, Kyungpook National University School of Medicine, Daegu, Korea Tel: +82753720C%5720, Fax: +82753742576683 EimaH: kimyhmd@knu.ac.Kr

Received 30 July 201510 September 2015 Accepted 10 September 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

We report the case of a 7-year-old boy who showed treatment-nonresponsive hypotension (59/29 mmHg) and decreased left ventricular systolic function (fractional shortening 22%) in the acute stage of Kawasaki disease (KD). The present case serves to highlight that methylprednisolone pulse therapy should be considered in patients with intravenous immunoglobulin nonresponsive symptomatic myocarditis during the acute stage of KD.

Keywords: Kawasaki disease, Corticosteroids, Myocarditis

REFERENCES

1. Falcini F, Capannini S, Rigante D. Kawasaki syndrome: an intriguing disease with numerous unsolved dilemmas. Pe—diatr Rheumatol Online I. 2011; 9:17.

2. Newburger JW, Fulton DR. Kawasaki disease. Curr Opin Pediatr. 2004; 16:508— 14.

3. Kim GB, Han JW, Park YW, Song MS, Hong YM, Cha SH, et al. Epidemiologic features of Kawasaki disease in South Korea: data from nationwide survey, 2009—201 1. Pediatr Infect Dis I. 2014; 33:24–7.

4. Kuwabara M, Yashiro M, Kotani K, Tsuboi S, Ae R, Naka—mura Y, et al. Cardiac lesions and initial laboratory data in Kawasaki disease: a nationwide survey in Japan. J Epidemiol. 2015; 25:189–93.

5. Aggarwal P, Suri D, Narula N, Manojkumar R, Singh S. Symptomatic myocarditis in Kawasaki disease. Indian I Pediatr. 2012; 79:813–4.

6. Yoshikawa H, Nomura Y, Masuda K, Hazeki D, Yotsumoto K, Arata M, et al. Four cases of Kawasaki syndrome complicated with myocarditis. Circ I. 2006; 70:202–5.

7. Schultheiss HP, Kuhl U, Cooper LT. The management of myocarditis. Eur Heart]. 2011; 32:2616–25.

8. Rosenfeld EA, Shulman ST, Corydon KE, Mason W, Takahashi M, Kuroda C. Comparative safety and efficacy of two immune globulin products in Kawasaki disease. I Pediatr. 1995; 26:1000–3.

9. Singh S, Rohit M, Gupta A, Suri D, Rawat A. Late sympto—matic myocarditis in Kawasaki disease: an unusual manifes—tation. Indian J Pediatr. 2014; 81:404–5.

10. Saneeymehri S, Baker K, So TY. Overview of pharmacological treatment options for pediatric patients with refractory ka—wasaki disease. I Pediatr Pharmacol Ther. 2015; 20:163–77.

11. Fan PC, Chiu CH, Yen MH, Huang YC, Li CC, Lin TY. School—aged children with Kawasaki disease: high incidence of cervical lymphadenopathy and coronary artery involvement. J Paediatr Child Health. 2003; 39:55–7.

Fig. 1.

Clinical course of the patient. CRP, C-reactive protein; IVIG, intravenous immunoglobulin; MP, methylprednisolone.

Fig. 2.

Change of ejection fraction (%, I), Z score of maximum diameter of right coronary artery (×), and Z score of diameter of left main coronary artery (A) according to the day of admission.

TOOLS

Similar articles